FinVector is an internationally renowned leader in the cGMP manufacturing of viral-based gene therapy products. The fast-growing company has nearly 30 years of cGMP manufacturing experience and currently offers its clients a wide array of services, including cell banking, viral seed stocks, platform process development, assay development, and aseptic filling capabilities. Based in Kuopio, Finland, the company is owned by Ferring Ventures, a subsidiary of Ferring Foundation B.V.